XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
 6 Months Ended
Feb. 28, 2025
Feb. 29, 2024
Cash flows from operating activities    
Net income $ 3,280,000 $ 5,974,000
Adjustments to reconcile net income to net cash provided by operating activities    
Depreciation and amortization 4,539,000 2,196,000
Change in fair value of contingent consideration (640,000) 330,000
Discharge of holdback obligation related to Immunetrics acquisition (224,000) 0
Amortization of investment discounts (60,000) (796,000)
Stock-based compensation 3,416,000 3,147,000
Deferred income taxes (907,000) (885,000)
Currency translation adjustments (68,000) (69,000)
(Increase) decrease in    
Accounts receivable (7,357,000) (2,913,000)
Prepaid income taxes 822,000 (560,000)
Prepaid expenses and other assets 376,000 (1,170,000)
Increase (decrease) in    
Accounts payable 604,000 216,000
Other liabilities (736,000) 1,145,000
Deferred revenue 1,350,000 (643,000)
Net cash provided by operating activities 4,395,000 5,972,000
Cash flows from investing activities    
Purchases of property and equipment (152,000) (433,000)
Purchase of short-term investments (5,000,000) (48,989,000)
Proceeds from maturities of short-term investments 3,620,000 36,252,000
Proceeds from sales of investments 995,000 0
Purchase of long-term investments 0 (9,024,000)
Purchased intangibles (342,000) (467,000)
Net working capital & excess cash settlement - Pro-ficiency acquisition (227,000) 0
Capitalized computer software development costs (1,348,000) (1,719,000)
Net cash used in investing activities (2,454,000) (24,380,000)
Cash flows from financing activities    
Payment of dividends 0 (2,394,000)
Payment for Contingent Consideration Liability, Financing Activities (1,576,000) 0
Proceeds from the exercise of stock options 316,000 310,000
Net cash used in financing activities (1,260,000) (2,084,000)
Net increase in cash and cash equivalents 681,000 (20,492,000)
Cash and cash equivalents, beginning of period 10,311,000 57,523,000
Cash and cash equivalents, end of period 10,992,000 37,031,000
Supplemental disclosures of cash flow information    
Income taxes paid 616,000 3,142,000
Right of use assets capitalized $ 451,000 $ 0